联合检测血清CA153、CA125、CA199对乳腺癌的临床意义

目的探讨血清CA153、CA125、CA199联合检测对乳腺癌早期诊断的价值。方法采用化学发光法分别检测乳腺癌、乳腺良性疾病患者、体检健康者血清中CA153、CA125、CA199的水平。结果乳腺癌患者血清CA153、CA125、CA199水平均显著高于正常组和良性乳腺疾病组，差异有统计学意义（P〈0.01）；乳腺癌患者术后CA153、CA125、CA199含量较术前显著性下降（P〈0．01），与正常组比较差异无统计学意义（P〉0.05）。CA153、CA125、CA199单独检测乳腺癌的灵敏度分别为54％、36％、30％，特异性为96．6％、91．6％、93．2％．准确性为84、2％、75．1％、74-8％。三者联合检测乳腺癌的灵敏度为78．0％、特异性为88．1％、准确性为85．2％。三项联合检测与单独检测相比灵敏度明显提高（P〈0．05）。结论联合检测血清标志物CA153、CA125、CA199的阳性率、敏感性有较大幅度的提高．三项标志物虽不能作为乳腺癌的特异性指标，但可为临床早期发现、诊断乳腺癌提供十分重要的依据。     

抗人CA50单克隆抗体的制备、鉴定及其应用北大核心CSCD

目的制备抗人糖抗原50（CA50）单克隆抗体（m Ab）,鉴定其免疫学特性并建立化学发光免疫分析法检测体系。方法将人CA50抗原免疫BALB/c小鼠,利用杂交瘤技术进行细胞融合,筛选后得到稳定分泌抗CA50抗体的杂交瘤细胞株。经细胞扩大培养及纯化获得m Ab后,建立化学发光免疫分析法检测体系,并对其线性范围、准确度、灵敏度、重复性进行评估,同时进行血样的测定。结果筛选出4株抗人CA50的杂交瘤细胞株,效价均在1∶108以上,2株配对抗体不与CA125、CA153、CA199、CA724交叉。建立的化学发光免疫分析法检测范围为0~500 U/m L,回收率为107.08%,灵敏度为0.83 U/m L,重复性CV值〈10%,与参比试剂检测血样的结果比较符合率为96.7%,Kappa值为0.911。结论成功制备了抗人CA50m Ab,建立了人CA50的化学发光免疫分析法检测体系。     

抗人CA50单克隆抗体的制备、鉴定及其应用

目的制备抗人糖抗原50(CA50)单克隆抗体(m Ab),鉴定其免疫学特性并建立化学发光免疫分析法检测体系。方法将人CA50抗原免疫BALB/c小鼠,利用杂交瘤技术进行细胞融合,筛选后得到稳定分泌抗CA50抗体的杂交瘤细胞株。经细胞扩大培养及纯化获得m Ab后,建立化学发光免疫分析法检测体系,并对其线性范围、准确度、灵敏度、重复性进行评估,同时进行血样的测定。结果筛选出4株抗人CA50的杂交瘤细胞株,效价均在1∶108以上,2株配对抗体不与CA125、CA153、CA199、CA724交叉。建立的化学发光免疫分析法检测范围为0~500 U/m L,回收率为107.08%,灵敏度为0.83 U/m L,重复性CV值10%,与参比试剂检测血样的结果比较符合率为96.7%,Kappa值为0.911。结论成功制备了抗人CA50m Ab,建立了人CA50的化学发光免疫分析法检测体系。     

血清CA19—9、CA125、CA242、CEA联检诊断胰腺癌的临床价值

目的：评价血清糖类抗原19—9（CA19—9），糖类抗原125（CA125），糖类抗原242（CA242）及癌胚抗原（CEA）四项指标联检对胰腺癌的诊断价值。方法：四项标志物均应用全自动化学免疫分析检测。结果：胰腺癌患者血清CA19—9、CA125、CA242、CEA水平明显高于胰腺良性病组，差异均有显著性（P〈0．01）。四项指标联检诊断胰腺癌的敏感性为91．7％，特异性92．1％。结论：血清CA19—9、CA125、CA242及CEA单项检测在胰腺癌诊断中特异性均偏低，且四项联检可提高胰腺癌的敏感性及特异性，临床诊断价值更大。     

抗人CA125单克隆抗体的制备、鉴定及化学发光体系的建立

目的制备抗人糖抗原125(CA125)单克隆抗体(mAb),并建立化学发光免疫分析法检测体系。方法将人CA125抗原免疫小鼠,通过细胞融合、筛选后得到杂交瘤细胞株。经细胞扩大培养及纯化获得mAb,鉴定其特异性、纯度、亚型及效价,并建立双抗体夹心ELISA。分别对包被缓冲液、包被浓度和加样模式进行优化和选择后,建立化学发光免疫分析法检测体系,并对其进行评估和血样的测定。结果获得3株抗人CA125的杂交瘤细胞株(30-1-4、31-1-5、43-1-6),不与CA199、CA50、CA724交叉,效价在1∶108以上,用30-1-4和31-1-5建立的化学发光免疫分析法经优化后,检测范围为0~1 000 U/mL,最低检测限为0.72 U/mL,与罗氏试剂检测结果的相关系数大于0.90。结论成功制备了抗人CA125 mAb,建立并优化了人CA125的化学发光免疫分析法检测体系,为CA125检测及卵巢癌的诊断奠定了基础。     

HIV／AIDS患者血清CA199、CA125、CA153检测的临床应用价值

目的研究HIV／AIDS患者血清糖类抗原CA199、CA125、CA153水平的变化，探讨其在HIV／AIDS患者的病情进展及疗效观察中的应用价值。方法对确诊的184例HIV／AIDS患者进行血清CA199、CA125、CA153和CD4＋T细胞的检测，并对检测结果进行比较分析。结果AIDS患者CA199、CA125、CA153值及阳性率显著高于HIV组和HIV／HBV／HCV组及健康对照者（P〈0．05），HIV／HBV／HCV组CA199、CA125、CA153值及阳性率显著高于HIV组和健康对照者（P〈0．05），CD4^＋T细胞数和血清CA199、CA125、CA153水平及异常率呈显著负相关。结论血清CA199、CA125、CA153对于HIV／AIDS的病情诊断及疗效观察具有较好的临床应用价值，建议对HIV感染者应常规进行血清CA199、CA125、CA153水平监测，积极治疗，改善预后。     

多肿瘤标志物蛋白芯片与化学发光检测临床应用的对比分析

目的:探讨多肿瘤标志物蛋白芯片与化学发光检测对肿瘤诊断的临床应用价值.方法:应用多肿瘤标志物蛋白芯片与化学发光技术,对180名健康体检者和已患肿瘤的210例病人进行12种肿瘤标志物联合检测,并对检测结果进行对比分析.结果:多肿瘤标志物蛋白芯片与化学发光检测两种方法在对健康体检组阳性率和特异性经统计学分析没有显著性差异(P＞0.05);对已患肿瘤的210例12种肿瘤标志物检测两种方法的检测结果为AFP 、 PSA、f-PSA、CA199、CA153、NSE有显著性差异(P＜0.05),CA242、β-HCG 、HGH、CA125、Fer、CEA没有显著性差异(P＞0.05).结论:多肿瘤标志物蛋白芯片与化学发光检测在对提高肿瘤诊断的阳性率和特异性方面具有一定的相关性,但多肿瘤标志物蛋白芯片在健康体检中的应用价值优于化学发光检测,而对确诊的肿瘤患者,化学发光检测优于多肿瘤标志物蛋白芯片检测.     

血清SCCA、CEA、CA125、CA19-9联合检测在宫颈癌与癌前病变鉴别诊断中的应用价值

目的探讨血清鳞状细胞癌抗原(SCCA)、癌胚抗原(CEA)、糖链抗原125(CA125)、糖链抗原199(CA19-9)联合检测在宫颈癌和宫颈癌前病变(CIN)鉴别诊断中的应用价值。方法回顾性分析2017年6月至2018年6月间收治36例CIN患者(CIN组)和68例宫颈癌患者(宫颈癌组)临床资料,并选取同期行健康体检者30例作为对照组。比较三组受试者血清肿瘤标志物SCCA、CEA、CA125、CA19-9水平,评估不同血清肿瘤标志物诊断宫颈癌的结果 ,绘制ROC曲线评估不同血清肿瘤标志物单独及联合检测诊断宫颈癌的效能。结果①三组SCCA、CEA、CA125、CA19-9对比,差异均有统计学意义(P<0.05);宫颈癌组SCCA、CEA、CA125、CA19-9均高于CIN组和对照组(P<0.05);CIN组SCCA、CEA、CA125、CA19-9均高于对照组(P<0.05);②SCCA、CEA、CA125、CA19-9单独诊断中,SCCA灵敏度、准确率、阳性预测值、阴性预测值及AUC均最高,CA125特异性最高;SCCA+CEA+CA125+CA19-9联合诊断的灵敏度、特异性、准确率、阳性预测值、阴性预测值及AUC均最高。结论宫颈癌、CIN和正常人群SCCA、CEA、CA125、CA19-9水平差异显著,SCCA、CEA、CA125、CA19-9联合诊断宫颈癌具有较高的诊断效能。     

ROC曲线评估相关肿瘤标志物对肺癌的诊断临界值

应用肿瘤标志物（TM）的灵敏度、特异性已受到一定程度的重视,而灵敏度和特异性取决于诊断临界值的选定。选定合适的诊断临界值或如何选定诊断临界值,对TM的评价很重要。ROC曲线对评价诊断性试验性能及确定最佳诊断临界值非常有用。本文用电化学发光免疫分析法检测癌胚抗原（CEA）、细胞角蛋白19片段（CYFRA21-1）、神经特异性烯醇化酶（NSE）、糖类抗原（CA125）等肺癌诊断（监测）相关肿瘤标志物,     

联合检测抑制素A、CA125与CA153在卵巢癌中的表达及临床意义

目的探讨联合检测血清抑制素A(INH-A)、CA125与CA153水平对卵巢癌早期诊断的价值。方法采用全自动化学发光免疫分析法(CLIA)检测卵巢癌组40例,卵巢良性疾病组30例,对照组30名健康女性的血清INH-A、CA125与CA153水平。结果卵巢癌组血清INH-A、CA125与CA153水平明显高于卵巢癌组和卵巢良性疾病组,差异有统计学意义(P<0.05);三项标志物的阳性率分别为52.5%,60.0%,72.5%,三项联合检测的阳性率为82.5%。卵巢癌组血清INH-A水平高于卵巢良性疾病组和对照组,提示INH-A异常表达可能与卵巢癌的发生密切相关。结论 INH-A可能作为诊断卵巢癌的一项肿瘤标志物,联合检测有助于早期诊断卵巢癌以及病情监测。     

两种不同方法学检测PSA、CA125、CA15-3、CA19-9的比对研究

为探讨不同检测方法测定PSA、CA125、CA15-3、CA19-9结果的可比性,参考EP9-A2文件的规定,使用RIA和微粒子酶免疫方法(MEIA)测定PSA、CA125、CA15-3及CA19-9并进行方法学比对试验,两种方法各项结果间均呈良好的线性关系,其相关系数R2均大于0.95;PSA和CA15-3系统误差均...     

血清CA19-9、CA242和CA50在胰腺癌诊断中的应用

目的 探讨血清肿瘤标志物CA19-9、CA242和CA50单项检测及联合检测在胰腺癌诊断中的应用价值.方法 选取胰腺癌患者59例(胰腺癌组)、胰腺良性疾病患者64例(胰腺良性疾病组),采用直接化学发光方法对患者血清中CA19-9、CA242、CA50水平进行检测,并比较分析单一肿瘤标志物检测及联合检测的的诊断价值.结果 胰腺癌患者血清CA19-9、CA242、CA50水平显著高于胰腺良性疾病组(P＜0.05),肿瘤标志物单项检测,CA19-9敏感性最高(81.36％),CA242特异性最高(84.78％),联合检测可提高检测的敏感性(平行试验联合检测)和特异性(系列试验联合检测).结论 CA19-9、CA242、CA50的联合检测对胰腺癌的诊断提供重要参考依据,具有较高的临床价值.     

血清CA125、CA15．3、CA242联合检测对乳腺癌诊断的价值

目的评价血清标志物糖类抗原125（CA125）、15．3（CA15．3）、242（CA242）联合检测对乳腺癌诊断的价值。方法对长海医院肿瘤科2003年9月至2005年9月期间收治的73例乳腺癌患者及60例健康人血清进行CA125、CA15．3、CA242检测。结果乳腺癌组三种肿瘤标志物检测的阳性率显著高于对照组（Х^2检验,P〈0．01）。乳腺癌组CA125、CA15．3、CA242及联合检测的阳性率由高到低依次为联合检测（68．49％）、CA15．3（49．32％）、CA125（34．25％）、CA242（28．77％）,CA15．3阳性率与三种标志物联合检测的阳性率差异有统计学意义（Х^2=5．546,P〈0．05）,即联合检测的阳性率高于CA15．3单独检测的阳性率。结论CA125、CA15．3、CA242联合检测能明显提高乳腺癌的检出率。     

AMIGO2 mRNA expression in hippocampal CA2 and CA3a

AMIGO2, or amphoterin-induced gene and ORF (open reading frame) 2, belongs to the leucine-rich repeats and immunoglobulin superfamilies. The protein is a downstream target of calcium-dependent survival signals and, therefore, promotes neuronal survival. Here, we describe the mRNA distribution pattern of AMIGO2 throughout the mouse brain with special emphasis on the hippocampus. In the Ammon’s horn, a detailed comparison between the subregional mRNA expression patterns of AMIGO2 and Pcp4 (Purkinje cell protein 4)—a known molecular marker of hippocampal CA2 (Cornu Ammonis 2)—revealed a prominent AMIGO2 mRNA expression level in both the CA2 and the CA3a (Cornu Ammonis 3a) subregion of the dorsal and ventral hippocampus. Since this CA2/CA3a region is particularly resistant to neuronal injury and neurotoxicity [Stanfield and Cowan (Brain Res 309(2):299–307 1984); Sloviter (J Comp Neurol 280(2):183–196 1989); Leranth and Ribak (Exp Brain Res 85(1):129–136 1991); Young and Dragunow (Exp Neurol 133(2):125–137 1995); Ochiishi et al. (Neurosci 93(3):955–967 1999)], we suggest that the expression pattern of AMIGO2 indeed fits with its involvement in neuroprotection.     

CA125 and endometriosis

This review covers the literature on CA125 and endometriosis; data on CA125 and oncology are not discussed. In normal women, plasma concentrations of CA125 are increased slightly at ovulation and significantly during menstruation. Marked increases are observed during pregnancy and following peritoneal irritation by infection or surgery. These data are consistent with the concept that CA125 in normal women is mainly derived from the endometrium and the irritated peritoneum. Plasma concentrations of CA125 are markedly elevated in women with cystic ovarian endometriosis and/or deeply infiltrating endometriosis, but not, or only slightly, in the luteal phase of women with minimal or mild endometriosis. This is consistent with the recent concept which considers minimal endometriosis as a normal condition occurring intermittently in many women, in contrast with deep endometriosis and cystic ovarian endometriosis which are called 'endometriotic disease'. Serum CA125 is not a good marker for endometriosis but it is a helpful additional parameter to diagnose endometriotic disease in patients with chronic pelvic pain. Following treatment of endometriosis, elevated plasma concentrations of CA125 could be used as an argument that treatment has been incomplete, or that the condition has recurred. Assaying CA125 in peritoneal fluid requires high sample dilutions or a modified immunoradiometric assay, and until now, its clinical value has been questionable.     

Somatostatin acts in CA1 and CA3 to reduce hippocampal epileptiform activity

Although the peptide somatostatin (SST) has been speculated to function in temporal lobe epilepsy, its exact role is unclear, as in vivo studies have suggested both pro- and anticonvulsant properties. We have shown previously that SST has multiple inhibitory cellular actions in the CA1 region of the hippocampus, suggesting that in this region SST should have antiepileptic actions. To directly assess the effect of SST on epileptiform activity, we studied two in vitro models of epilepsy in the rat hippocampal slice preparation using extracellular and intracellular recording techniques. In one, GABA-mediated neurotransmission was inhibited by superfusion of the GABAA receptor antagonist bicuculline. In the second, we superfused Mg2+-free artificial cerebrospinal fluid to remove the Mg2+ block of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. We show here that SST markedly reduces the intensity of evoked epileptiform afterdischarges and the frequency of spontaneous bursts in both CA1 and CA3. SST appears to act additively in the two regions to suppress the transmission of epileptiform events through the hippocampus. We further examined SST's actions in CA3 and found that SST dramatically reduced the frequency of paroxysmal depolarizing shifts (PDSs) recorded intracellularly in current clamp, as well as increasing the threshold for evoking "giant" excitatory postsynaptic currents (EPSCs), large polysynaptically mediated EPSCs that are the voltage-clamp correlate of PDSs. We also examined the actions of SST on pharmacologically isolated EPSCs generated at both mossy fiber (MF) and associational/commissural (A/C) synapses. SST appears to act specifically to reduce recurrent excitation between CA3 neurons because it depresses A/C- but not MF-evoked EPSCs. SST also increased paired-pulse facilitation of A/C EPSCs, suggesting a presynaptic site of action. Reciprocal activation of CA3 neurons through A/C fibers is critical for generation of epileptiform activity in hippocampus. Thus SST reduces feedforward excitation in rat hippocampus, acting to "brake" hyperexcitation. This is a function unique from that described for other hippocampal neuropeptides, which affect more standard neurotransmission. Our results suggest that SST receptors could be a unique, selective clinical target for treatment of limbic seizures.     

肿瘤标志物CA19-9、CA242、CA125在胰腺癌诊断和预后评估中的价值

为了评价CA19-9、CA242、CA125单独或联合检测在胰腺癌诊断和预后评估中的作用,对105例确诊的胰腺癌患者,手术前检测血清CA19-9、CA242、CA125值,并检测了70例非胰腺恶性肿瘤患者和30例良性胰腺疾病患者的血清CA19-9、CA242、CA125水平.结果发现,单独应用于胰腺癌诊断时,CA19-9的灵敏度最高,但是其特异性显著低于CA242和CA125(P＜0.01).联合检测CA125和CA242可使诊断特异性达到92%.CA242高于正常值的胰腺癌患者,其生存期明显短于CA242值正常的胰腺癌患者(P＜0.05).三项肿瘤标志物中两项以上高于正常值的患者,其生存期显著低于仅有一项高于正常值或三项皆正常的患者(P＜0.05).CA19-9在胰腺癌诊断率方面优于CA125和CA242.联合使用CA125和CA242可以提高诊断的特异性.肿瘤标志物高水平与胰腺癌进展期相关.三项肿瘤标志物中两项或三项高于正常值的患者其生存期较短.